|
Complement C3c
|
D015932 |
[A 206-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c (749-954), and C3dg (955-1303) in the presence COMPLEMENT FACTOR H.
] |
|
Pluripotent Stem Cells
|
D039904 |
[Cells that can give rise to cells of the three different GERM LAYERS.
] |
|
Complement C3d
|
D015933 |
[A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001).
] |
|
Complement Membrane Attack Complex
|
D015938 |
[A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC.
] |
|
Lead Poisoning, Nervous System
|
C25.723.522.750.500 |
|
|
Kitasamycin
|
D015939 |
[A macrolide antibiotic produced by Streptomyces kitasatoensis. The drug has antimicrobial activity against a wide spectrum of pathogens.
] |
|
Complement C5a
|
D015936 |
[The minor fragment formed when C5 convertase cleaves C5 into C5a and COMPLEMENT C5B. C5a is a 74-amino-acid glycopeptide with a carboxy-terminal ARGININE that is crucial for its spasmogenic activity. Of all the complement-derived anaphylatoxins, C5a is the most potent in mediating immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE), smooth MUSCLE CONTRACTION; HISTAMINE RELEASE; and migration of LEUKOCYTES to site of INFLAMMATION.
] |
|
Cleft Palate
|
C07.650.500.460.185 |
|
|
Complement C5a, des-Arginine
|
D015937 |
[A derivative of complement C5a, generated when the carboxy-terminal ARGININE is removed by CARBOXYPEPTIDASE B present in normal human serum. C5a des-Arg shows complete loss of spasmogenic activity though it retains some chemotactic ability (CHEMOATTRACTANTS).
] |
|
Acetylation
|
G02.111.012.052 |
|
|
Factor XI
|
D08.622.490 |
|
|
Dwarfism
|
C19.297 |
|
|
Codonopsis
|
B01.650.940.800.575.912.250.171.200 |
|
|
Diet Records
|
D015930 |
[Records of nutrient intake over a specific period of time, usually kept by the patient.
] |
|
Intensive Care, Neonatal
|
D015931 |
[Continuous care and monitoring of newborn infants with life-threatening conditions, in any setting.
] |
|
Interferon beta-1b
|
D23.529.374.440.890.275.750 |
|
|
Histamine Agents
|
D27.505.519.625.375 |
|
|
Aspartate Aminotransferases
|
D08.811.913.477.700.225 |
|
|
Magnetite Nanoparticles
|
J01.637.512.600.500.144.500 |
|
|
Auditory Diseases, Central
|
D001304 |
[Disorders of hearing or auditory perception due to pathological processes of the AUDITORY PATHWAYS in the CENTRAL NERVOUS SYSTEM. These include CENTRAL HEARING LOSS and AUDITORY PERCEPTUAL DISORDERS.
] |
